Home
CERO
CERO News

Latest CERo Therapeutics Holdings Inc. Common Stock (CERO) News on November 18, 2024

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

GlobeNewswire

2 days ago

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

GlobeNewswire

7 days ago

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Provides Corporate Update

GlobeNewswire

a month ago

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

GlobeNewswire

2 months ago

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

GlobeNewswire

2 months ago

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

GlobeNewswire

4 months ago

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

GlobeNewswire

5 months ago

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Edge Total Intelligence Inc. Updates Status of MCTO

Newsfile

5 months ago

Edge Total Intelligence Inc. Updates Status of MCTO

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

CNW Group

5 months ago

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024

GlobeNewswire

5 months ago

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers

GlobeNewswire

5 months ago

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting

GlobeNewswire

5 months ago

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

GlobeNewswire

5 months ago

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

CNW Group

5 months ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

PR Newswire

5 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

ACCESSWIRE

5 months ago

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

GlobeNewswire

5 months ago

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

GlobeNewswire

6 months ago

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes

GlobeNewswire

7 months ago

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes

Business Wire

8 months ago

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Business Wire

9 months ago

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

Share on Social Networks: